These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 35753058)

  • 1. Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?
    Abdelhamid M; Rosano G; Metra M; Adamopoulos S; Böhm M; Chioncel O; Filippatos G; Jankowska EA; Lopatin Y; Lund L; Milicic D; Moura B; Ben Gal T; Ristic A; Rakisheva A; Savarese G; Mullens W; Piepoli M; Bayes-Genis A; Thum T; Anker SD; Seferovic P; Coats AJS
    Eur J Heart Fail; 2022 Sep; 24(9):1460-1466. PubMed ID: 35753058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modern heart failure treatment is superior to conventional treatment across the left ventricular ejection spectrum: real-life data from the Swedish Heart Failure Registry 2013-2020.
    Karlström P; Pivodic A; Dahlström U; Fu M
    Clin Res Cardiol; 2024 Sep; 113(9):1355-1368. PubMed ID: 39186181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of heart failure pharmacotherapies in patients with heart failure with mildly reduced ejection fraction.
    Schupp T; Bertsch T; Reinhardt M; Abel N; Schmitt A; Lau F; Abumayyaleh M; Akin M; Weiß C; Weidner K; Behnes M; Akin I
    Eur J Prev Cardiol; 2024 Aug; 31(11):1347-1360. PubMed ID: 38513366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guideline-Directed Medical Therapy Before and After Primary Prevention Implantable Cardioverter Defibrillator Implantation in New Zealand (ANZACS-QI 66).
    Foo FS; Lee M; Poppe KK; Clare GC; Stiles MK; Gavin A; Webber M; Jackson R; Kerr AJ
    Heart Lung Circ; 2022 Nov; 31(11):1531-1538. PubMed ID: 35999128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis.
    Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK
    Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
    Vaduganathan M; Claggett BL; Jhund PS; Cunningham JW; Pedro Ferreira J; Zannad F; Packer M; Fonarow GC; McMurray JJV; Solomon SD
    Lancet; 2020 Jul; 396(10244):121-128. PubMed ID: 32446323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
    Xiang B; Zhang R; Wu X; Zhou X
    JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurohormonal Antagonists Are Preferred to an Implantable Cardioverter-Defibrillator in Preventing Sudden Death in Heart Failure.
    Packer M
    JACC Heart Fail; 2019 Oct; 7(10):902-906. PubMed ID: 31521684
    [No Abstract]   [Full Text] [Related]  

  • 10. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction.
    Sandhu AT; Kohsaka S; Turakhia MP; Lewis EF; Heidenreich PA
    JAMA Cardiol; 2022 Feb; 7(2):130-139. PubMed ID: 34757380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy.
    Malgie J; Clephas PRD; Brunner-La Rocca HP; de Boer RA; Brugts JJ
    Heart Fail Rev; 2023 Sep; 28(5):1221-1234. PubMed ID: 37311917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
    Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity.
    DeFilippis EM; Butler J; Vaduganathan M
    Circ Heart Fail; 2017 Nov; 10(11):. PubMed ID: 29138249
    [No Abstract]   [Full Text] [Related]  

  • 15. A risk score to predict the absence of left ventricular reverse remodeling: Implications for the timing of ICD implantation in primary prevention.
    Pérez-Rodon J; Galve E; Pérez-Bocanegra C; Soriano-Sánchez T; Recio-Iglesias J; Domingo-Baldrich E; Alzola-Guevara M; Ferreira-González I; Marsal JR; Ribera-Solé A; Gutierrez García-Moreno L; Cruz-Carlos LM; Rivas-Gandara N; Roca-Luque I; Francisco-Pascual J; Evangelista-Masip A; Moya-Mitjans À; García-Dorado D
    J Cardiol; 2018 May; 71(5):505-512. PubMed ID: 29183646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction.
    Tromp J; Ouwerkerk W; van Veldhuisen DJ; Hillege HL; Richards AM; van der Meer P; Anand IS; Lam CSP; Voors AA
    JACC Heart Fail; 2022 Feb; 10(2):73-84. PubMed ID: 34895860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Chronic Heart Failure in Advanced Chronic Kidney Disease: The HAKA Multicenter Retrospective Real-World Study.
    Quiroga B; Ortiz A; Núñez S; Kislikova M; González Sanchidrián S; Broseta JJ; Albines ZS; Escamilla Cabrera B; Rivero Viera Y; Rodriguez Santarelli D; Salanova Villanueva L; Lopez Rodriguez F; Cancho Castellano B; Ibáñez Cerezon M; Gutierrez Rivas CP; Aresté N; Campos Gutiérrez B; Ródenas Gálvez A; Glucksmann Pizá MC; Balda Manzanos S; Soldevila A; Rodríguez Gayo L; Moral Berrio E; Ortega Diaz M; Beltrán Catalán S; Puente García A; Ángel Rojas M; Sosa Barrios RH; Santana Zapatero H; Rangel Hidalgo G; Martinez Canet AM; Díez J;
    Cardiorenal Med; 2024; 14(1):202-214. PubMed ID: 38513622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
    Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
    Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta-analysis.
    Danielson C; Lileikyte G; Ouwerkerk W; S P Lam C; Erlinge D; Teng TK
    ESC Heart Fail; 2022 Aug; 9(4):2753-2761. PubMed ID: 35603531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin receptor/neprilysin inhibitor-a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings.
    Książczyk M; Lelonek M
    Heart Fail Rev; 2020 May; 25(3):393-402. PubMed ID: 31713710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.